Navigation Links
Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development
Date:5/18/2011

LA JOLLA, Calif., May 18, 2011 /PRNewswire/ -- Anaphore Inc. today announced that Michael F. Haller, Ph.D., and H Casey Logan have joined Anaphore's senior management team.

Dr. Haller will be responsible for managing Anaphore's research and development partnership with Mitsubishi Tanabe Pharma Corporation, additional collaborative projects, and assisting senior management in shaping Anaphore's corporate strategy. Mr. Logan will work with senior management to execute Anaphore's strategic business plans, including securing additional partnerships and potential future fundraising activities.

"The appointments of Michael and Casey reflect the progress that we are making with the platform and the forward direction of our drug discovery efforts at the company," said Katherine Bowdish, Ph.D., chief executive officer of Anaphore. "Michael, with his demonstrated expertise in alliance management, will play an integral role in the success of our partnership with Mitsubishi Tanabe to develop protein therapeutics for the treatment of autoimmune disorders. Casey's business acumen will be valuable in our business development efforts including discussions with other companies also interested in partnering with Anaphore."

Dr. Haller joins Anaphore from Halozyme Therapeutics, where, as vice president of alliance management and portfolio development, he directed key alliances with Roche and Baxter Healthcare. Prior to Halozyme, Dr. Haller was a McKinsey & Company management consultant focusing on complex health care issues for a number of Fortune 500 companies. Dr. Haller has published several peer-reviewed articles, presented at numerous scientific conferences, and is co-inventor on multiple patents. Dr. Haller earned his Ph.D. in biomedical engineering from The Johns Hopkins University School of Medicine, his M.S. in chemical engineering from Cornell University, and his B.S. in biomedical engineering from The Johns Hopkins University.

Mr. Logan previously led corporate development and strategic planning efforts at Anadys Pharmaceuticals. Prior to Anadys, he was with Eli Lilly and Company in the corporate business development group. Mr. Logan has led transactions in both in-licensing and out-licensing of assets across a range of therapeutic areas, including the creation of two new companies, CoLucid Pharmaceuticals and Muroplex Therapeutics. Prior to Lilly, Mr. Logan was an officer in the U.S. Naval Nuclear Propulsion Program. Mr. Logan received his M.B.A. from the Kellogg School of Management at Northwestern University and B.S.E. in chemical engineering from the University of Michigan.

About Anaphore

Anaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Each of the three binding domains comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest.  Atrimer therapeutics potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies.  Atrimer protein therapeutics are protected by intellectual property, including multiple patent families.

Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimer therapeutics against targets in a wide range of therapeutic areas, including rare diseases.

Anaphore recently formed a partnership with Mitsubishi Tanabe Pharma Corporation to discover and develop Atrimer drug candidates for the treatment of autoimmune disorders. Since its founding in 2008, Anaphore has raised $38 million in financing from top-tier biotechnology investors 5AM Ventures, Versant Ventures, Apposite Capital LLP, SR One, Merck Serono Ventures and Aravis SA.

For more information please visit www.anaphore.com.

Media Contact:
Ian Stone or David Schull
Russo Partners, LLC
619-528-2220
ian.stone@russopartnersllc.com
david.schull@russopartnersllc.com


'/>"/>
SOURCE Anaphore Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
2. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
3. Cepheid Appoints LABSCO as US Small Hospital Distributor
4. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
5. Xanodyne Pharmaceuticals Appoints New Chief Operating Officer
6. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
7. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer
8. Qforma Appoints New Member to Board of Directors
9. Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
10. Abaxis Appoints Vernon Altman to Board of Directors
11. Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
Breaking Medicine News(10 mins):